Overview of direct oral anticoagulant therapy reversal.

作者: Michael P. Gulseth

DOI: 10.2146/AJHP150966

关键词:

摘要: Purpose Strategies for the management of bleeding complications and facilitation an invasive procedure in patients receiving direct oral anticoagulants (DOACs) are reviewed. Summary The DOACs provide clinical advantages versus vitamin K antagonists, including fixed dosing with no routine coagulation monitoring evidence a lower risk bleeding. However, as all anticoagulants, there is DOACs, so urgent reversal their anticoagulant activity may be required spontaneous or traumatic events undergoing emergency procedures. Reversal strategies dependent on involved, location severity bleeding, and/or urgency procedure. recently approved specific agent dabigatran, idarucizumab, together other agents development will hopefully allow emergent without increasing underlying thrombosis. research to determine optimal use these agents, terms choice agent, dosing, concomitant management. A systematic approach implementation hospitals also ensure that physicians, nurses, pharmacists receive appropriate education have necessary protocols guidelines manage situations. Conclusion DOAC need tailored involved well situation. should help facilitate anticoagulation who require surgery, though agents.

参考文章(45)
Charles V. Pollack, Paul A. Reilly, John Eikelboom, Stephan Glund, Peter Verhamme, Richard A. Bernstein, Robert Dubiel, Menno V. Huisman, Elaine M. Hylek, Pieter W. Kamphuisen, Jörg Kreuzer, Jerrold H. Levy, Frank W. Sellke, Joachim Stangier, Thorsten Steiner, Bushi Wang, Chak-Wah Kam, Jeffrey I. Weitz, Idarucizumab for Dabigatran Reversal The New England Journal of Medicine. ,vol. 373, pp. 511- 520 ,(2015) , 10.1056/NEJMOA1502000
Charles Frost, Sunil Nepal, Jessie Wang, Alan Schuster, Wonkyung Byon, Rebecca A. Boyd, Zhigang Yu, Andrew Shenker, Yu Chen Barrett, Rogelio Mosqueda‐Garcia, Frank LaCreta, Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects British Journal of Clinical Pharmacology. ,vol. 76, pp. 776- 786 ,(2013) , 10.1111/BCP.12106
Hein Heidbuchel, Peter Verhamme, Marco Alings, Matthias Antz, Hans-Christoph Diener, Werner Hacke, Jonas Oldgren, Peter Sinnaeve, A John Camm, Paulus Kirchhof, Advisors:, Azhar Ahmad, Jutta Heinrich-Nols, Susanne Hess, Markus Müller, Felix Münzel, Markus Schwertfeger, Martin Van Eickels, Isabelle Richard-Lordereau, Gregory YH Lip, Chern-En Chiang, Jonathan Piccini, Tatjana Potpara, Laurent Fauchier, Deirdre Lane, Alvaro Avezum, Torben Bjerregaard Larsen, Guiseppe Boriani, Vanessa Roldan-Schilling, Bulent Gorenek, Irene Savelieva, None, Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. ,vol. 17, pp. 1467- 1507 ,(2015) , 10.1093/EUROPACE/EUV309
DA Henry, PA Carless, AJ Moxey, D O'Connell, BJ Stokes, B McClelland, A Laupacis, D Fergusson, Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion Cochrane Database of Systematic Reviews. ,vol. 2007, ,(2011) , 10.1002/14651858.CD001886.PUB4
Felix Schiele, Joanne van Ryn, Keith Canada, Corey Newsome, Eliud Sepulveda, John Park, Herbert Nar, Tobias Litzenburger, None, A specific antidote for dabigatran: functional and structural characterization. Blood. ,vol. 121, pp. 3554- 3562 ,(2013) , 10.1182/BLOOD-2012-11-468207
Genmin Lu, Francis R DeGuzman, Stanley J Hollenbach, Mark J Karbarz, Keith Abe, Gail Lee, Peng Luan, Athiwat Hutchaleelaha, Mayuko Inagaki, Pamela B Conley, David R Phillips, Uma Sinha, A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa Nature Medicine. ,vol. 19, pp. 446- 451 ,(2013) , 10.1038/NM.3102
Thomas Thiele, Kathleen Selleng, Andreas Greinacher, Reversal of anticoagulants: an overview of current developments Thrombosis and Haemostasis. ,vol. 113, pp. 931- 942 ,(2015) , 10.1160/TH14-11-0982
W. Frank Peacock, Michelle M. Gearhart, Roger M. Mills, Emergency Management of Bleeding Associated With Old and New Oral Anticoagulants Clinical Cardiology. ,vol. 35, pp. 730- 737 ,(2012) , 10.1002/CLC.22037
Viktoria Moschetti, Stephen Norris, Joachim Stangier, Michael Schmohl, Joanne van Ryn, Benjamin Lang, Steven Ramael, Paul Reilly, Stephan Glund, A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran Thrombosis and Haemostasis. ,vol. 113, pp. 943- 951 ,(2015) , 10.1160/TH14-12-1080